Sign up Canada
Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

Dr Lang is an internationally renowned cardiologist and specialist in echocardiography..
VentriPoint Diagnostics reveals that University of  Chicago will assess its heart analysis system
The VMS plus heart analysis system can provide data on all four chambers.

VentriPoint Diagnostics Ltd (CVE:VPT) told investors that the University of Chicago's medical centre is to assess the its innovative VMS plus  heart analysis system.

With the recent market clearance from the key FDA, Chicago will be one of the first sites to evaluate and publish on the performance of the VMS+ system compared to MRI for all four cardiac chambers, spearheaded by Dr Roberto Lang, said the company.

"We are very pleased to have the VMS+ system installed in a very busy clinical environment such as the Department of Medicine at the University of Chicago," said Desmond Hirson, president of Ventripoint.

"We believe that our product in the hands of the non-invasive cardiac imaging laboratory under the direction of Dr. Lang , will make a valuable difference to patient outcomes."

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI) to render 3D volumes for all four chambers of the heart providing clinicians with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

Dr Lang is an internationally renowned cardiologist and specialist in echocardiography, the study of heart function using sound waves.

He uses vast knowledge of cardiac imaging techniques to evaluate patients with a wide variety of heart conditions, including heart failure and valve disease, noted Ventripoint.

Dr George Adams, chief executive of Ventripoint, noted that Dr Lang had been "one of the leading doctors" who encouraged the firm to expand the VMS to include all four chambers of the heart and not just the RV to address the unmet need in many heart conditions.

"We have proven to the FDA that the VMS+ is accurate and reliable, but we did this ourselves, and it needs independent verification, which the University of Chicago will provide," he added.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use